Efficient gene expression by self-complementary adeno-associated virus serotype 2 and 5 in various human cancer cells

Area of Science:

• Biotechnology
• Molecular Biology
• Oncology

Background:

• Gene therapy requires efficient and specific delivery vehicles for therapeutic payloads.
• Adeno-associated virus (AAV) vectors are promising for gene delivery due to their low immunogenicity and broad tropism.
• Self-complementary AAV (scAAV) vectors offer faster transgene expression kinetics compared to single-stranded AAV vectors.

Purpose of the Study:

• To evaluate the feasibility of various scAAV serotypes for gene delivery in human cancer cells.
• To compare the transduction efficiency and transgene expression duration of different scAAV serotypes.
• To identify optimal scAAV vectors for potential cancer gene therapy applications.

Main Methods:

• Infection of diverse human cancer cell lines with scAAV1-6 and scAAV8 vectors expressing Green Fluorescent Protein (GFP).
• Assessment of transduction efficiency via GFP expression levels at various Multiplicities of Infection (MOI).
• Monitoring of transgene expression duration over one month post-transduction.

Main Results:

• scAAV2 demonstrated the highest transduction efficiency, achieving near-complete transgene expression in most cancer cells.
• scAAV5 also showed effective gene expression, though less potent than scAAV2.
• Both scAAV2 and scAAV5 enabled transgene expression lasting over a month, indicating long-term gene expression potential.
• Co-infection with scAAV2 and scAAV5 resulted in simultaneous transgene expression from both vectors.

Conclusions:

• scAAV2 and scAAV5 are highly effective gene transfer tools for a broad range of human cancer cells.
• These vectors facilitate persistent transgene expression, crucial for sustained therapeutic effects.
• scAAV2 and scAAV5 represent promising candidates for developing novel cancer gene therapies.